Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03886831 · ClinicalTrials.gov registry record · Phase 1
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
A Phase 1 study, sponsored by Prelude Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 232
- Enrollment target
NCT03886831: Completed Phase 1 study, sponsored by Prelude Therapeutics.
NCT03886831 is a Phase 1 study that has completed, run by Prelude Therapeutics. The registered enrollment target is 232 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (287% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03886831, a Phase 1 study, has completed, sponsored by Prelude Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 232 participants
- Enrollment target
Study Summary
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.
Primary Outcome
Dose limiting toxicities (DLTs) will be evaluated during the first cycle
Interventions
- DRUG PRT543
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 1 |
What the finished NCT03886831 record still lists
NCT03886831 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (287% higher).
The record links to 0 conditions, and to 1 intervention - of which PRT543 is the first listed.
NCT03886831 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03886831 about?
NCT03886831 is a clinical study titled "A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies". This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.
What is the current status of trial NCT03886831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2019-02-11. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT03886831?
The interventions under investigation include: PRT543 (DRUG).
Who is sponsoring clinical trial NCT03886831?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03886831's enrollment target sits among peer trials
232 216th of 2000 higher than 1,784 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI